Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Clinical Therapeutics|February 13, 2016
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes MellitusCarol Addy, Daniel Tatosian, Xiaoli S Glasgow, et al.Clinical and Translational Science|November 27, 2024
Assessment of pharmacokinetics and tolerability following single-dose administration of molnupiravir in participants with hepatic or renal impairmentKelly E Duncan, Russ P Carstens, Kristin L Butterfield, et al.Journal of Tissue Engineering|May 22, 2023
Single-cell RNA-sequence analysis of human bone marrow reveals new targets for isolation of skeletal stem cells using spherical nucleic acidsElloise Z Matthews, Stuart Lanham, Kate White, et al.Scientific Data|May 23, 2018
Gridded birth and pregnancy datasets for Africa, Latin America and the CaribbeanW H M James, N Tejedor-Garavito, S E Hanspal, et al.Journal of Clinical Pharmacology|October 1, 2003
Pharmacokinetics of etoricoxib in patients with hepatic impairmentNancy G B Agrawal, Mark J Rose, Catherine Z Matthews, et al.Journal of Clinical Pharmacology|March 18, 2003
Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in manNancy G B Agrawal, Arturo G Porras, Catherine Z Matthews, et al.Journal of Clinical Pharmacology|September 3, 2004
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activityNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.Journal of Clinical Pharmacology|December 19, 2003
Pharmacokinetics of etoricoxib in patients with renal impairmentNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.Pageof 3